Eagle Pharmaceuticals, Inc. · OTC:EGRX

Eagle Pharmaceuticals — Corporate Update (March 2021)

9 slides from Eagle Pharmaceuticals's corporate update, Mar 2, 2021

  1. Slide 1: Investor Update March 2, 2021

    1 1 INVESTOR Update March 2, 2021

  2. Slide 2: Forward-Looking Statements

    2 Forward - Looking Statements This presentation contains forward - looking information within the meaning of the Private Securities Litigation Reform Act of 199 5, as amended, and other securities laws. Forward - looking statements are statements that are not historical facts. Words and phrases suc

  3. Slide 3: EA-114 (Fulvestrant)

    3 3 EA - 114 (Fulvestrant)

  4. Slide 4: EA-114 (Fulvestrant) Insights and Path Forward

    4 EA - 114 (Fulvestrant) Insights and Path Forward ▪ Eagle conducted two clinical trials comparing Eagle’s formulation to Faslodex® ▪ These studies followed 750 subjects for 140 - 280 days ▪ Analyzed thousands of collected data points and discerned the need for a distinctive delivery system ▪ Sought

  5. Slide 5: Nerve Agent Medical Countermeasure

    5 5 Nerve Agent Medical Countermeasure

  6. Slide 6: Eagle's Nerve Agent Medical Countermeasure Program

    6 Eagle’s Nerve Agent Medical Countermeasure Program Eagle has put forth a significant amount of effort in developing Ryanodex for the treatment of brain damage secondary to nerve agent toxicity. Proof of Concept study using rat soman model conducted at MRIGlobal ( EGL - DTL - NC - 1704 ) Pivotal Go

  7. Slide 7: Proof-of-Concept Study: MRIGlobal EGL-DTL-NC-1704

    7 Proof - of - Concept Study: MRIGlobal - EGL - DTL - NC - 1704 The positive outcome of this study provided the basis for the design of an adequately powered GLP study in a well - established rat model of soman exposure. Fronto - Parietal Cortex: Photomicrographs Fronto - Parietal Cortex: Mean Necro

  8. Slide 8: Pivotal GLP Study in Rat Soman Model

    8 Pivotal GLP Study in Rat Soman Model: USAMRICD - SR - 1 - 19 - U - 1091 Photomicrographs: Fronto - Parietal Cortex Most neurons were necrotic (denoted by black arrows) and only a few neurons (denoted by white arrows) were unaffected

  9. Slide 9: Nerve Agent Medical Countermeasure Program Next Steps

    9 Nerve Agent Medical Countermeasure Program Next Steps 9 We are planning further studies in Non - Human Primate soman models The FDA agrees with our model selection and has requested that Eagle submit a SPA for review prior to conducting the pivotal GLP studies Eagle will conduct preliminary PK/PD

Eagle Pharmaceuticals — Corporate Update (March 2021) on 6ix